Full Press Release Details
Inc. Issued Full Patent from the Chinese National Intellectual Property Administrant for Its "Abuse and Misuse Deterrent Transdermal
FL / ACCESSWIRE / October 31, 2024 / Nutriband (NASDAQ:NTRB)(NASDAQ:NTRBW), has announced that the Chinese National Intellectual
Property Administrant (CNIPA) has fully issued its patent titled "Abuse and Misuse Deterrent Transdermal System" which
is related to the Company's lead technology AVERSA .
patent underpins 4p Therapeutics' abuse deterrent transdermal system, AVERSA, which uses taste aversion to address the primary routes
of abuse for opioid based transdermal patches. The patent number reflects the issuance of Patent
No: ZL 202211158031.
CNIPA issued a prior notice of allowance in September 2024.
AVERSA Abuse-Deterrent Transdermal Technology
Nutriband's AVERSA abuse-deterrent transdermal technology incorporates aversive agents into transdermal patches to prevent the
abuse, diversion, misuse, and accidental exposure of drugs with abuse potential. The AVERSA abuse-deterrent technology has the
potential to improve the safety profile of transdermal drugs susceptible to abuse, such as fentanyl, while making sure that these drugs
remain accessible to those patients who really need them. The technology is covered by a broad intellectual property portfolio with patents
granted in the United States, Europe, Japan, Korea, Russia, Canada, Mexico, and Australia.
We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development
is an abuse-deterrent fentanyl patch incorporating our AVERSA abuse-deterrent technology. AVERSA technology can be incorporated
into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
Company's website is www.nutriband.com. Any material contained in or derived from the Company's websites or any other website is
not part of this press release.
Certain statements contained in this press release, including, without limitation, statements containing the words 'believes,"
"anticipates," "expects" and words of similar import, constitute "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks
and uncertainties. The Company's actual results may differ materially from those anticipated in its forward-looking statements as a result
of a number of factors, including those including the Company's ability to develop its proposed abuse-deterrent fentanyl transdermal
system and other proposed products, its ability to obtain patent protection for its abuse technology, its ability to obtain the necessary
financing to develop products and conduct the necessary clinical testing, its ability to obtain Federal Food and Drug Administration
approval to market any product it may develop in the United States and to obtain any other regulatory approval necessary to market any
product in other countries, including countries in Europe, its ability to market any product it may develop, its ability to create, sustain,
manage or forecast its growth; its ability to attract and retain key personnel; changes in the Company's business strategy or development
plans; competition; business disruptions; adverse publicity and international, national and local general economic and market conditions
and risks generally associated with an undercapitalized developing company, as well as the risks contained under "Risk Factors"
and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the Company's Form 10-K for
the year ended January 31, 2024, filed May 1, 2024, the Forms 10-Q's filed subsequent to the Form 10-K in 2024, and the Company's other
filings with the Securities and Exchange Commission. Except as required by applicable law, we undertake no obligation to revise or update
any forward-looking statements to reflect any event or circumstance that may arise after the date hereof.
RedChip Companies, Inc.
Email: NTRB@Redchip.com
Phone: 1-800-RED-CHIP (733-2447)
431 E Horatio Ave, Suite #100
Email: info@nutriband.com